References:
  1. Gupta A, Thompson D, Whitehouse A, et al. 2017. Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase. Lancet 2017;389:2473-2481.
  2. Mammen, Andrew L. 2016. Statin-Associated Autoimmune Myopathy N Engl J Med 2016; 374:664-669
  3. Nazir S, Lohani S, Tachamo N, Poudel D, Donato A. 2017. Statin-Associated Autoimmune Myopathy: A Systematic Review of 100 Cases. J Clin Rheumatol. 2017 Apr;23(3):149-154.
  4. Gu HM, Zhang DW. 2015. Hypercholesterolemia, low density lipoprotein receptor and proprotein convertase subtilisin/kexin-type 9. J Biomed Res . 2015;29(5):356-361. doi:10.7555/JBR.29.20150067
  5. Oesterle A, Liao JK. 2019. The Pleiotropic Effects of Statins - From Coronary Artery Disease and Stroke to Atrial Fibrillation and Ventricular Tachyarrhythmia. Curr Vasc Pharmacol . 2019;17(3):222-232. doi:10.2174/1570161116666180817155058
  6. Lucile Musset, Yves Allenbach, Olivier Benveniste, Olivier Boyer, Xavier Bossuyt, et al. 2016. Anti-HMGCR antibodies as a biomarker for immune-mediated necrotizing myopathies: A history of statins and experience from a large international multi-center study. Autoimmunity Reviews 15 (2016) 983–993